Base Genomics

About:

Base Genomics is an epigenetics company focusing on developing a blood test for early-stage cancer and minimal residual disease.

Website: https://www.basegenomics.com/

Twitter/X: BaseGenomics

Top Investors: Oxford Science Enterprises

Description:

Base Genomics is an epigenetics company based on TAPS (TET-assisted pyridine borane sequencing), a new invention to sequence DNA methylation developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford. TAPS is a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike bisulfite sequencing, TAPS does not degrade DNA, meaning that more DNA is available for sequencing. It also retains sequence complexity, cutting sequencing costs and enabling simultaneous epigenetic and genetic analysis.